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ABSTRACT
Significant advances have been made towards understanding the role of immune 
cell-tumor interplay in either suppressing or promoting tumor growth, progression, and 
recurrence, however, the roles of additional stromal elements, cell types and/or cell 
Meeting Report
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states remain ill-defined. The overarching goal of this NCI-sponsored workshop was 
to highlight and integrate the critical functions of non-immune stromal components 
in regulating tumor heterogeneity and its impact on tumor initiation, progression, 
and resistance to therapy. The workshop explored the opposing roles of tumor 
supportive versus suppressive stroma and how cellular composition and function may 
be altered during disease progression. It also highlighted microenvironment-centered 
mechanisms dictating indolence or aggressiveness of early lesions and how spatial 
geography impacts stromal attributes and function. The prognostic and therapeutic 
implications as well as potential vulnerabilities within the heterogeneous tumor 
microenvironment were also discussed. These broad topics were included in this 
workshop as an effort to identify current challenges and knowledge gaps in the field.
INTRODUCTION
The last two decades have seen significant gains 
in unveiling the crosstalk between cancer cells and the 
stroma within which they reside. This complex mixture 
of interacting cells can be considered as a dynamic 
multidimensional ecosystem that regulates tumor growth, 
inherent and acquired plasticity/heterogeneity, invasion, 
and metastasis. The expansion of cancer research 
beyond a cell autonomous-based model has enabled the 
identification and characterization of a wide range of 
cell types including fibroblasts, immune, endothelial, 
neuronal, and specialized mesenchymal cells that regulate 
the formation of a tumor-permissive and therapy-resistant 
environment. In addition, a deeper appreciation for the 
role that the extracellular matrix (ECM) plays in this 
ecosystem has emerged. Despite these advances, much of 
the scientific focus has remained primarily centered on the 
tumor cells and on driver mutations that dictate stromal 
reprogramming to support tumor growth. These include 
oncogene-mediated tumor cell proliferation, reactive 
oxygen species (ROS)/hypoxia-induced regulation of 
the endothelium, inflammation-associated angiogenesis 
and immune-suppression, and metabolic reprogramming 
of stromal fibroblasts and adipocytes to offset tumor 
cell nutrient deprivation [1–5]. Studies in these areas 
have collectively uncovered numerous mechanisms by 
which cancer cells manipulate the microenvironment to 
support tumor growth. However, many aspects of the 
biological alterations that arise in stromal cell types or in 
the extracellular matrix components that may drive cancer 
initiation or progression remain poorly understood.
The traditional view of driver mutations 
within incipient tumor cells instructing each step of 
tumorigenesis has influenced basic cancer researchers 
and drug developers alike to focus on genetically and 
molecularly profiling tumor cell autonomous mechanisms 
for targetable vulnerabilities. The foundational principle 
of “a tumor cell as an organizer” [6] also gave rise to 
precision medicine as a promising blueprint and path 
forward to more effective mutation- or target-specific 
therapeutic strategies. Unfortunately, only modest 
improvements in clinical outcomes have resulted from 
these approaches. Aggressive tumor phenotypes resulting 
from targeted therapy, such as small cell lung cancers 
and neuroendocrine prostate tumors following EGFR- 
and AR-targeted inhibition [7, 8], respectively, prompted 
the community to conclude that narrow tumor cell and 
mutational status-centric approaches alone are unlikely 
to succeed. The realization that successful combination 
therapies in broad tumor types required an understanding 
of the complexity of tumor-tumor microenvironment 
(TME) dynamics and heterogeneity led to the development 
of immune-oncology and checkpoint inhibitors. The 
availability of research tools, experimental models, and 
clinical reagents in the field of immunology has enabled 
the rapid rise and validation of novel mechanism-based 
approaches to modulate the immune microenvironment. 
The delivery of durable remission induced by anti-
programmed cell death protein 1 (PD-1)/programmed 
death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) immune checkpoint 
inhibitors in a subset of cancer types and patients has 
motivated many basic and translational investigators to 
focus their attention and resources towards studying the 
role of the immune cell-tumor interplay in cancer growth, 
progression, and recurrence [9–11]. However, only a 
subset of patients benefit from immunotherapies and little 
is known about the contribution of non-immune stromal 
cell types and extracellular matrix components to these 
processes, and even less is known about how these stromal 
functions and interactions differ throughout each stage of 
disease progression [11, 12]. Nevertheless, these successes 
raise the possibility that further disease altering targets 
reside in the TME, awaiting discovery.
Limited, yet pivotal studies demonstrating the 
importance of non-immune stromal components in 
shaping the fate of tumors exist, but remain poorly 
understood and underpowered. Examples of work that 
must be expanded include understanding the role of non-
immune stroma in regulating immune cell recruitment 
to tumor sites, driving chronic inflammation-induced 
DNA damage in preneoplasia, characterizing and 
tracing different carcinoma-associated fibroblasts (CAF) 
functional subtypes and their roles in different states as 
both promoters and suppressors of tumor progression, 
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and the direct causal relationship between acellular 
stroma, ECM remodeling and/or age-related senescence-
associated secretory phenotype (SASP) in inducing a 
field-effect conducive to malignant conversion.
An ongoing challenge in studying these non-
immune stromal programs is that the models are still 
limited. Appropriate and highly specific Cre-drivers that 
allow for dynamic fate mapping of these cells are often 
lacking. Limited studies have genetically manipulated 
these stromal cell types in an unbiased manner using 
shRNA and/or CRISPR approaches. This is essential 
for discovering new functional aspects of stroma-tumor 
crosstalk to move it from correlation to causality. Current 
models that will enable these discoveries include more 
rapid mouse transgenic models, complex organoid models, 
as well as zebrafish and flies, the latter of which are 
particularly amenable to screens of this sort.
Expanding the notion that stroma, along with the 
tumor cells, co-organizes all stages of tumorigenesis 
will lay the foundation for a broad spatial and temporal 
understanding of the complete TME from initiation 
through metastasis. In order to assess the challenges 
associated with this goal, the NCI’s Division of Cancer 
Biology sponsored a workshop that built upon the advances 
in the immune-oncology realm and emphasized non-
immune stromal components. The workshop highlighted 
the critical functions of the non-immune stromal cell types 
and ECM in regulating heterogeneity and tumor cell fate 
throughout initiation, progression, and therapy resistance. 
The workshop not only explored the multifaceted role of 
stroma in suppressing and/or supporting tumorigenesis 
in early and advanced stage cancers, but also considered 
emerging themes of stromal plasticity and position-
dependent functions of stromal subtypes in driving 
disease progression, resistance to therapy, and as possible 
clinical targets of vulnerability. These workshop topics 
were consolidated within five themes that addressed key 
scientific and technical challenges related to 1) stromal-
centric arbiters of tumor progression and suppression; 2) 
the unique biology of early lesions in regulating indolence 
versus aggressiveness; 3) stromal plasticity and its role in 
regulating the fate of the tumor mass; 4) the significance of 
stromal cell geography and architecture in cancer; and 5) 
clinical implications of microenvironmental heterogeneity.
Stromal-centric arbiters of tumor progression 
and suppression
Stroma contributes to both suppressing and 
promoting tumor progression, yet what cell subtypes, 
ECM components, and underlying mechanisms regulate 
tumor fate in varying contexts, including aging, genetic 
background, and systemic comorbidities, remain ill-
defined. Studies conducted on fibroblasts and CAFs as 
a major stromal element have contributed significantly 
in the recent past to characterizing the heterogeneity of 
the microenvironment and important leads are beginning 
to emerge that elucidate distinct functions of different 
subtypes in these diametrically opposing functions. In 
the first talk of the session, Raghu Kalluri highlighted the 
functional diversity of tumor-restraining (αSMA+) and 
tumor-promoting (FAP+) CAF subtypes in a mouse model 
of pancreatic ductal adenocarcinoma (PDAC). αSMA+ 
CAFs predominantly modulate ECM production, facilitate 
cell-ECM adhesion, and regulate adaptive immunity [13]. 
Simon Hayward shifted the focus to human prostate 
cancer models and provided evidence of CAF subtypes 
with distinct expression signatures revealed by single cell 
RNA-seq analysis. CAF clusters differ in their chemokine/
cytokine profiles, leading to cluster-specific effects on 
the microenvironment – such as macrophage recruitment 
via high CCL2 expressing CAFs or modulation of 
inflammatory cells by high CXCL12-expressing CAFs. 
Specific populations of recruited populations (depending 
on the CAF subtype) can produce distinct factors that 
will shape the tumor and/or microenvironment in distinct 
ways – e.g., macrophage-derived pro-tumorigenic factors, 
recruitment of other immune cell types that promote the 
M2-macrophage phenotype [14]. 
In her presentation, Ellen Puré focused on reactive 
CAFs expressing fibroblast activation protein positive 
(FAP+) in mouse PDAC. In contrast to normal stromal 
cells that maintain epithelial integrity and confer tumor 
resistance, FAP+ fibroblasts have immunosuppressive 
and tumor promoting properties. Indeed, both the Puré 
and Kalluri laboratories have provided evidence that 
human PDAC patients with FAP+ fibroblasts have 
decreased survival compared to αSMA+ fibroblasts [13, 
15]. FAP+ fibroblasts display increased ECM alignment 
[16] and synthesis, yet lower contractility and ECM 
crosslinking, while displaying higher levels of paracrine 
growth factors and inflammatory gene expression profiles 
[17]. Mechanistically, Puré highlighted a novel ECM-
informed stromagenic switch – regulated by multiple 
factors including substratum stiffness, PDGF, TGFβ, 
sonic hedgehog, and osteopontin – that contributes 
to CAF heterogeneity and is a key component of the 
transition from a tumor-resistant to a tumor-permissive 
microenvironment [18]. 
David Tuveson discussed findings from his team 
involving the identification of additional CAF subtypes 
classified as either myogenic myCAFs, inflammatory 
iCAFs, or the most recently isolated and characterized 
antigen presenting apCAFs that express MHC class II 
and CD74 and are capable of activating CD4+ T cells, 
but lack other immune related genes including classical 
co-stimulatory molecules [19, 20]. Studies by his group 
using 3D organoid and mouse models suggest that CAF 
heterogeneity is in part driven by IL-1β and TGFβ 
antagonism, resulting in iCAFs and myCAFs that either 
promote or inhibit tumor growth, respectively [21]. 
Single-cell mRNA-seq of human PDAC also putatively 
Oncotarget3624www.oncotarget.com
identified these two CAF subpopulations [19]. He further 
highlighted the inherent, position-dependent plasticity 
between CAF subtypes, suggesting these are functional 
fibroblastic states, as opposed to static fibroblast types. 
The topic of cellular plasticity was expanded further 
by Ashani Weeraratna in her discussions of the aging 
stroma in a mouse model of melanoma. She summarized 
data that suggest age-associated events contribute to 
altering the function of CAFs in a tissue-specific manner 
and with important implications to not just tumorigenesis 
and metastasis but also therapeutic outcomes. For instance, 
aged lung fibroblasts (but not aged skin fibroblasts 
from human donors) drive proliferation via induction 
of canonical Wnt signaling [22]. In contrast, aged skin 
fibroblasts exhibit enhanced sFRP2-driven non-canonical 
Wnt signaling that triggers a phenotypic switch to a non-
proliferative, yet highly invasive and BRAFi-resistant 
mesenchymal state [22]. This BRAFi/MEKi resistance 
is further propagated by the secretion of lipids by aged 
fibroblasts, which drive metabolic changes in melanoma 
cells in aged microenvironment (Alicea, Rebecca et al. 
2020). Targeting these age-related changes overcame 
therapy resistance in animal models, suggesting that the 
TME may provide a rich source of targetable moieties.
Fibroblasts and other stromal cell types in the tumor 
microenvironment acquire pro- and/or anti-tumorigenic 
phenotypes that impact carcinoma growth. Research 
in this area has identified heterogeneity in CAF marker 
expression and function, altered functions of fibroblasts 
based on tissue source, and plasticity of fibroblasts among 
cell states. A greater understanding of this functional 
heterogeneity and determining the degree of plasticity in 
other stromal cell types will elucidate novel mechanisms 
of tumor promotion and/or suppression, which may have 
therapeutic potential. 
Biology of early lesions: indolence versus 
aggressiveness
It has become increasingly clear that the TME 
changes throughout disease progression, but the 
involvement of stromal cells is primarily studied with 
regard to established and more advanced stages of cancer 
(e.g., metastasis). The contribution of stromal cells and the 
ECM to tumor initiation has not been widely studied, but 
some research in this area using diverse approaches has 
opened exciting avenues for further investigation.
Wu-Min Deng actively investigates tissue 
environments which are susceptible or resistant to tumor 
formation using a Drosophila model. He described that, 
upon knockdown of a tumor suppressor gene scrib, 
specific regions within developing fly tissues would 
reject tumor growth while other regions would allow 
tumor growth. This identified “tumor hotspots” in which 
JAK/STAT signaling was determined to be elevated [23, 
24]. Further analysis of transition cells of imaginal rings 
revealed that notch signaling drives mitosis in these 
polyploid cells [24]. These studies provide evidence 
that signaling events within specific microenvironments 
can enable tumor formation. Understanding the “tumor 
hotspot” and “tumor coldspot” microenvironments and 
what controls the definition of these regions may aid in 
cancer prevention or have therapeutic potential.
Philip Beachy highlighted work from his group 
demonstrating stromal suppression of growth in tumors of 
endodermal origin. In bladder cancer, tumors are almost 
completely clonal in origin, and using a mouse bladder 
cancer model his group determined that sonic hedgehog 
(Shh)-expressing cells act as long-term stem cells that 
regenerate the bladder epithelium via Wnt signaling 
[25, 26]. Precancerous bladder epithelium is still Shh+ 
but expression is lost in invasive carcinoma [26]. The 
transition to invasive carcinoma may be linked to loss of 
bone morphogenic proteins (BMP) in the adjacent stromal 
tissue, since BMP treatment promotes differentiation and 
blocks invasion in a mouse model of bladder cancer [26].
Another approach to investigating stromal 
involvement in early cancer lesions was described by 
Mara Sherman, who studies stromal evolution with 
pancreatic stellate cells (PSCs). Work by her group is 
focused on understanding the origins of fibroblasts within 
the TME in mouse PDAC. PSCs give rise to the PDAC 
CAF phenotype, but other non-PSC-derived CAFs exist as 
well. Using known markers of fibroblasts, such as desmin 
and podoplanin (PDPN), she indicated that some PDAC 
CAFs were PSC-derived while other CAFs were PDPN-
positive, non-PSC-derived CAFs [27]. She provided new 
evidence that activated PSCs contain less lipid droplets 
compared to pre-activated, and fatty acid binding protein 4 
(FABP4) may be used as a marker for PSC-derived CAFs 
in PDAC tissues [28]. However, more work is needed 
to identify reliable markers for various CAF subsets to 
further understand this heterogeneity. 
The discussion of this session was expanded further 
by Ken Lau, who uses computational modeling in colon 
cancer to identify CAF-cancer cell interactions that 
drive tumor progression [29]. His studies indicate that 
CAFs dominate the signaling networks of cell surface 
receptor-ligand interactions, specifically during epithelial-
mesenchymal transition (EMT) and in inflammatory 
nodules (unpublished data). Noninvasive colon cancer cells 
may also express EMT markers, so these are not unique to 
metastatic cells. His laboratory identified that PDGFRα+ 
CAFs are adjacent to cancer cells in colon cancer tissue 
specimens while αSMA+ myofibroblasts are more distant, 
indicating potentially unique functions of these fibroblast 
subsets as the disease progresses and underscoring the 
importance of geographic location within a developing and 
metastasizing tumor (unpublished data). Research by the 
Lau group and others in this session highlighted the exciting 
opportunities for discovery in the area of early-stage tumor 
biology. Further investigation of stromal evolution is 
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necessary to understand the biological importance to tumor 
formation at different stages as well as to evaluate stage-
specific therapeutic implications in these diseases. 
Stromal plasticity and communication
Complete knowledge of the TME requires an 
understanding of the many cell types and interactions 
within it. Unfortunately, the complexity of these 
interactions makes this work technically and conceptually 
difficult. Some of these interactions cannot be adequately 
studied because appropriate tools have not yet been 
developed. Thus, one of the objectives of this meeting 
was to discuss interactions between all cell types within 
the TME, including fibroblasts, adipocytes, immune 
cells, endothelial cells, nerves, normal epithelial cells, 
and cancer cells, as well as to discuss current limitations 
associated with researching intercellular communication.
Throughout the last decade, our understanding of 
cancer-immune cell interactions has been significantly 
advanced and has even led to successful new therapeutic 
strategies. PD-L1 targeting is one example of recently 
discovered therapeutic options, but clinical applications 
of PD-1/PD-L1 therapies have identified limitations, 
specifically by driving resistance mechanisms in tumors 
[11]. Current work by Jorge Moscat’s research group 
has shown that PD-L1 treatment works by revitalizing 
CD8+ T cell infiltration in a mouse model of serrated 
colorectal cancer, but only in young mice in which tumors 
have not yet developed a reactive stroma [30]. In older 
mice with highly desmoplastic tumors, PD-L1 treatment 
does not restore CD8+ T cells and consequently has no 
curative activity. This finding suggests that dual stromal 
activation impairs immune checkpoint blockade therapy, 
which was demonstrated to be the case by Moscat’s lab 
by targeting of TGFβ, which enhanced PD-L1 targeting 
efficiency [30]. Furthermore, analysis of how stromal cells 
may impair PD-L1 therapy suggests that CAF can block 
antigen presentation. Consideration of additional stromal 
contributors in this context as well as systemic factors, 
such as age, will elucidate superior therapeutic options. 
While the role of some immune cell populations, 
notably T cells and tumor-associated macrophages, have 
been widely studied in the context of the TME, this is an 
active area of research in which novel findings continue 
to evolve our understanding of immune cell-tumor cell 
dynamics and their potential implications in shaping tumor 
evolution. Melissa Wong and her group have recently 
characterized a cell fusion of macrophages with cancer 
cells [31]. These cancer hybrid cells acquire macrophage 
gene expression profiles and retain macrophage behavior, 
but are also capable of initiating tumors and can be 
detected in peripheral blood of patients [31, 32]. While 
most studies involving circulating tumor cells (CTCs) 
use cytokeratin+CD45- as the schema for detecting 
CTCs, Wong’s group discovered that hybrid cells that 
are cytokeratin+CD45+ make up more than 90% of 
circulating cancer cells [32]. This discovery suggests 
that fusogenic events between CD45- epithelial cells and 
CD45+ macrophages are at play in the TME in addition 
to more widely appreciated cell-cell interactions and that 
these events may impact tumor progression.
Significant efforts are currently in progress to target 
immune cells, so discussions at this meeting put greater 
emphasis on other cell types in the microenvironment 
that have not been so widely studied. Adipose tissue, for 
instance, is very dynamic and may serve as a nutrient source 
for cancer cells. Ernst Lengyel works to understand the 
microenvironmental contributions to human ovarian cancer 
metastasis and the metabolic co-dependencies between 
cancer and stromal cells. Metastasis to the omentum, 
the common site in this disease, leads to the localized 
disappearance of adipose tissue in the affected area. Dr. 
Lengyel’s group has provided evidence that this loss is 
likely due to the contributions of adipose tissue lipids and 
FABP4 to the tumor cells [33]. Ovarian cancer cells become 
loaded with lipid droplets after co-culture with adipocytes 
[34]. Similarly, the Hayward lab shows that prostate CAFs 
also maintain increased lipid droplet density compared to 
normal prostate fibroblasts, which aid in prostate cancer cell 
growth in vitro [35, 36]. Conversely, activation of primary 
PSCs yielded significantly less lipid droplets compared to 
pre-activated PSCs, but nevertheless suggest a link between 
stroma-derived lipids and tumor metabolism and growth 
[28]. However, the source of these lipids, the role they play 
in individual stromal cell types, and whether these differ in 
unique cancer types remain to be seen.
To further elucidate the role of lipids and adipose 
tissue in the TME, James Granneman’s laboratory 
investigates adipogenic niches and the stromal/immune 
cells that are key to adipose tissue maintenance, 
remodeling, and may play a role in tumor progression. 
scRNA-seq of mouse adipose tissue by his group identified 
two major adipocyte stem cell (ASC) subpopulations, 
ASC1 and ASC2, in epididymal and inguinal white 
adipose tissue that express different collagens and trophic 
factors, such as neurotrophin 3 and bone morphogen 7 
[37]. The ASC1 subpopulation expresses higher levels of 
PPARγ, a master regulator of adipogenesis, as well as the 
adipogenesis markers caveolin-1 and G0/G1 switch 2 – 
and appear to be primed for adipogenesis compared with 
ASC2 cells. The Granneman lab has begun to map the 
trajectory of adipose tissue in mouse cancer models. In 
these studies, tumor-bearing mammary fat pads underwent 
ASC population shifts from ASC2 to ASC1 in tumor-
bearing mice as well as changes in macrophage expression 
patterns linked to inflammatory responses, such as 
increased Trem2 and Irf8 [37]. This work aims to discover 
how adipose tissue changes in cancer and mechanisms by 
which this evolution contributes to malignant progression. 
Richard White further expanded the discussion of 
stromal-cancer cell interactions by discussing his work 
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using zebrafish melanoma models. The zebrafish is ideal 
for this given the optical transparency of the casper 
strain, which allows for powerful in vivo imaging [38]. 
Melanomas are surrounded by two cell types organized 
into a distinct geography, with keratinocytes above the 
lesion and adipocytes below the lesion. Prior work from 
the White lab showed that adipocytes are major drivers 
of melanoma progression by donating fatty acids to the 
tumor cell [39], which is consistent with other work in 
ovarian cancer [40]. What is less understood is how the 
keratinocytes, which are normal epithelial components 
of skin, drive progression. Using a BRAFV600E induced 
transgenic melanoma model [41] and real-time in vivo 
imaging, the White lab found that tumor cells export a 
variety of extracellular vesicles such as melanosomes 
and exosomes into the seemingly normal keratinocytes. 
The recipient keratinocytes then undergo reprogramming 
and switch from a tumor suppressive to tumor promoting 
role. These reprogrammed keratinocytes exhibit an 
N-myc pluripotency signature and dramatic alterations 
in chromatin structure. Although the absolute number of 
keratinocytes that undergo such reprogramming is small, 
their importance in promoting melanoma progression 
highlights the need for a detailed understanding of the 
“geography” of tumor-stroma interactions [42]. 
In other cancer models, such as renal cell carcinoma, 
the environmental context of cancer epithelial cells 
drastically influences the invasion potential of epithelial 
tumor cells. David Beebe’s models that incorporate 
compartmentalized epithelial and endothelial duct-based 
organotypic platforms, indicate that incubation of tumor 
epithelium with normal endothelium promotes invasion 
of the endothelial cells. However, incubation of tumor 
epithelium with cancer associated endothelium only 
yields cancer cell invasion without endothelial invasion. 
The Beebe lab continues to lead the development of cell-
cell interaction and microfluidic models for the study of 
unanswered biological questions [43, 44]. Use of these 
models and others will be essential to understanding 
the role of specific stromal cell types, intercellular 
communication, and the role of ECM components in the 
TME. 
The significance of stromal cell geography and 
architecture
The late Dr. Patricia Keely revolutionized the TME 
field by demonstrating that architectural organization of 
the ECM (including tumor cell distribution/localization) 
is fundamental to tumor cell-stromal cell interactions, 
metastasis, and response to therapy [45–48]. A stromal/
ECM barrier or tumor cell location within the TME may 
not only create nutrient/growth factor gradients, but 
also serve as a source of exogenous physical forces that 
may reprogram tumor cells and potentially function as a 
barrier against cancer therapy and adaptive immune cell 
destruction. Stromal stiffness, for instance, can signal 
normal epithelial cells to adopt malignant phenotypes [49, 
50], while dormant tumor cells have been suggested to 
resist chemotherapy by residing within the perivascular 
niche [51]. Therefore, a better understanding of tumor 
architecture and histology can provide important 
knowledge about how stromal cells organize themselves 
around the tumor cells and dictate their function/
phenotype. 
Despite recent technological advances, such as 
imaging mass cytometry and co-detection by indexing 
(CODEX) [52], histological analyses remain limited due 
to reliance on pre-existing antibodies. To overcome this 
limitation, Joakim Lundeberg has recently developed 
Spatial Transcriptomics (Visium from 10X Genomics, 
Inc.), a tool that combines tissue imaging with barcode 
array-based sequence transcriptomics. This tool allows for 
standard microscopy of fresh frozen sections to be coupled 
with spatial mRNA-seq, and ultimately visualization of 
imaging patterns, clonal tumor populations and stromal 
areas within intact tissues. Key findings include the 
identification of discrete stromal regions around prostate 
tumors that were nonresponsive to treatment [53]. As 
they expand the analysis, new fibroblast expression 
datasets under development will help identify CAFs 
of different origins and functions within the TME. The 
spatial interaction between stroma and various tumor 
subpopulations at the leading edge has recently been 
investigated in squamous cell carcinoma [54].
Next, Kristian Pietras showed that breast cancer 
CAFs from a mouse model are characterized by three 
distinct transcriptional programs, potentially reflecting 
unique spatial origins within the TME [55]. The largest 
CAF populations were enriched for angiogenic genes 
(vCAF) reflecting a perivascular origin. The second 
most abundant CAF population showed a significant 
increase in the expression of ECM-associated genes, 
suggesting tissue-resident fibroblasts as the source for this 
specific CAF subtype. The third, scarce CAF cluster was 
characterized by the expression of development-associated 
genes and were provisionally named developmental 
CAFs (dCAF). dCAFs show some overlapping gene 
expression with tumor epithelium, suggesting that dCAFs 
may originate from cancer cells that underwent EMT. 
The combination of Pietras’s CAF dataset with spatial 
transcriptomics may provide interesting data regarding 
the real spatial localization of these CAF subtypes within 
the TME.
Ruth Scherz-Shouval discussed transcriptomic 
data from a murine breast cancer model obtained using 
single-cell RNA-seq at different time points along 
tumor progression and metastasis. Her group identified 
two distinct CAF populations, each of which could be 
further dissected into subsets that change as tumors 
progress. These CAF subtypes, sCAF and pCAF, were 
characterized by high expression of S100A4 and PDPN, 
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respectively, and found in both mouse and human breast 
tumors. Interestingly, a higher sCAF/pCAF ratio was 
indicative of better overall survival in human patients, 
suggesting that the sCAF population may play a protective 
role against tumor progression [56]. Identifying specific 
subsets of CAFs that are associated with better therapeutic 
response and survival will allow researchers to leverage 
the function of these CAFs and bring precision treatment 
to patients with tumor-permissive CAF subtypes within 
their TME. However, as the characterization of CAF 
subtypes advances, the field will need to put further effort 
into standardizing the nomenclature and markers of these 
unique CAF populations (i.e., lineages and functions). 
Doing so will help integrate the findings from different/
independent research groups.
Katerina Politi shifted the focus to discuss how 
tumor intrinsic-targeted therapies are impacted by the 
organs affected by metastases. As mentioned above, these 
approaches have limited benefits, since tumors may, 
in part, undergo clonal selection upon targeted-therapy 
eventually culminating in a more aggressive tumor. For 
example, in EGFR-mutant lung tumors, resistance to first 
and second generation tyrosine kinase inhibitors (TKIs) 
is mostly driven by the emergence of a secondary T790M 
mutation in EGFR. To overcome this resistance, a third 
generation TKI, osimertinib, is currently used clinically, 
but patients can still develop resistance and many of the 
resistance mechanisms are poorly understood. To unravel 
the underlying mechanism, Politi and colleagues are 
investigating therapeutic responses in different metastatic 
sites. Early data support the idea that the TME location 
can impact sensitivity to TKIs. It is well known that 
different tumor sites can differentially impact tumor 
progression. Hence, the field needs to advance towards 
a better characterization of the molecular and cellular 
mechanisms that drive increased tumor progression in 
an organ and location-specific manner. Concomitantly, 
improved comprehension of the specific sites in the body 
that more potently restrict tumor cell proliferation could 
also provide valuable knowledge about stromal/tumor 
interactions that drive tumor progression.
The meeting also tackled the question of endothelial 
heterogeneity. Ying Zheng discussed the dynamic nature 
of the tumor microvasculature and how it changes during 
tumor progression. Zheng noted that many ongoing studies 
still work with specific cell lines that do not recapitulate 
the heterogeneity found in endothelial cells of different 
tissues. It is also important to consider the interactions of 
endothelial cells with their surroundings, which contain 
diverse cell types, ECM, and geometric complexities. 
Taking this into consideration, Zheng engineered a device 
that allows endothelial cells to reconstruct 3D vessel 
structures using fetal endothelial cells from different 
tissues. This technology aided in determining that 
endothelial cells with distinct tissue origins do indeed form 
vessels with diverse architecture and unique transcription 
profiles [57]. Studies regarding ECM influence on 
microvasculature architecture and gene expression are 
ongoing and will help elucidate the crosstalk between 
endothelial cells originating in different organs and their 
surroundings. Many questions still need to be addressed 
in order to completely understand microvasculature 
formation and function in tumors, including endothelial 
cell plasticity and how tumor cell or tissue location 
impacts endothelial cell behavior and microvasculature 
structure and function.
The present level of characterization of CAFs, 
adipocytes and endothelial cells has brought valuable, 
but less than comprehensive information about their 
function within the TME.  Nevertheless, it will help 
develop a necessary expansion in the field to identify new 
opportunities for targeted therapies. Better understanding 
the role of the non-immune stroma in shaping the 
microenvironment prior to the appearance of a tumor 
is also pivotal to unravelling the mechanisms driving 
tumorigenesis. A key issue is the high degree of stromal 
cell plasticity driven by multiple environmental vectors, 
creating a challenge to working with them in an ex vivo 
setting. Another looming challenge is to define cell states 
versus subtypes, particularly in CAFs. Also, work toward 
identifying triggers of cellular plasticity versus a more 
permanent epigenetic state is needed. This work will lay 
the groundwork for the field to move more deeply into the 
mechanisms that drive changes in the TME and impact 
tumorigenesis.
Prognostic and therapeutic implications of 
microenvironmental heterogeneity
During the final session, discussions were focused 
on the implications of current cancer therapy in the TME. 
Despite recent advances in targeted and immunotherapies, 
the core of cancer treatment is based on genotoxic agents, 
such as ionizing radiation and chemotherapy. Those agents 
exert systemic and local damage in non-tumor cells that 
consequently impact therapy-associated comorbidities 
and cancer recurrence. In this context, Sheila Stewart 
discussed her findings related to the impact of senescence 
in chemotherapy-induced bone loss, a common 
comorbidity in cancer patients. Using a genetic mouse 
model, her team found that elimination of senescent cells 
that arise after chemotherapy prevented bone loss [58]. In 
addition, targeting SASP pathways using pharmacological 
inhibition of p38MAPK/MK2 signaling also limited 
chemotherapy-induced side effects [58]. Senescence is 
not only triggered by chemotherapy but occurs normally 
in healthy individuals, as part of the aging process, and 
may directly impact tumorigenesis. Senescent fibroblasts 
upon SASP expression behave similarly to CAF regarding 
their ability to directly support tumor growth [59]. Stewart 
highlighted that limiting SASP signaling pathways reduces 
metastatic growth in a breast cancer setting. Her group 
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found that inhibition of p38MAPK/MK2 signaling 
restrained metastatic growth in the bone and visceral 
organs, through tumor cell-independent mechanisms 
[60]. However, the stromal cells where p38MAPK/MK2 
signaling exerts a deleterious role in metastatic growth 
remain to be elucidated.
Besides SASP, chemotherapy-induced genotoxic 
stress can trigger a DNA damage secretory program 
(DDSP) – very similar to SASP but not associated with 
cell cycle arrest and/or p16 signaling– releasing numerous 
inflammatory (IL-6/8), angiogenic (VEGF, CXCL1), 
mitogenic (amphiregulin), pro-EMT (HGF) and chemo-
preventative factors. Focusing on the potential effects of 
genotoxic stress in the TME, Peter Nelson showed that 
human prostate fibroblasts upregulate numerous pro-
tumorigenic factors upon a variety of genotoxic stimuli. 
Among the released factors, WNT ligands attenuate a 
cytotoxic chemotherapy effect in vivo when expressed 
in the prostate TME [61]. He highlighted the therapeutic 
potential of targeting these chemotherapy-induced 
factors, many of which are downstream of NF-κB and 
mTOR pathways. Despite the fact that NF-κB does not 
currently constitute a viable target, mTOR signaling can 
be targeted by many available drugs (e.g., rapamycin). 
Interestingly, fibroblasts that have been previously treated 
with rapamycin do not confer chemotherapy resistance 
to prostate cancer cells in vitro and in vivo. These 
data support ongoing clinical trials to assess whether 
rapamycin-induced inhibition of DDSP in prostate cancer 
patients under chemotherapy treatment can improve 
response. Other druggable DDSP pathways, including 
PARP inhibition to attenuate the DDSP and the NKG2D-
MIC-MMP axis to eliminate damaged cells with immune-
suppressive phenotypes, are also under consideration for 
future studies to identify new opportunities for stroma-
targeted therapies [62]. 
Neil Bhowmick expanded on the stromal 
considerations for prostate cancer therapy by presenting 
findings that demonstrated chemotherapy-triggered 
crosstalk between CAFs and tumor cells. His team found 
that docetaxel induces mitophagy and ER stress in prostate 
tumor cells, leading to secretion of mitochondrial DNA 
(mtDNA) [63]. This results in TLR9 activation in CAFs 
and release of C3a, a complement protein. Interestingly, 
C3a-induced activation of the C3a receptor in prostate 
cancer cells drives docetaxel resistance in mouse models. 
mtDNA was also found in the plasma of docetaxel-treated 
patients supporting the hypothesis that therapy resistance 
in prostate cancer patients may occur by this crosstalk 
[63]. In mouse models, combination therapy of docetaxel 
with a C3aR inhibitor showed increased efficacy in 
limiting tumor growth when compared to docetaxel alone. 
Future studies to unravel stromal-mediated chemotherapy 
resistance mechanisms may support the development 
of stroma-targeted therapies that improve current 
chemotherapy response in different types of cancer.
Finally, Edna Cukierman discussed the stromal 
heterogeneity found in the desmoplastic environment of 
pancreatic tumors. Her group found that fibroblastic cell 
function depends on the fibroblastic ECM. She showed 
that the desmoplastic ECM sustains the expression 
of Netrin G1 in PDAC CAFs while tumor adjacent 
fibroblasts cultured in “normal” ECM do not express 
this protein. Netrin G1 is a glycosylphosphatidylinositol-
anchored protein known for its glutamatergic pre-
synaptic function. Interestingly, the Netrin G1 binding 
partner, NGL1, is overexpressed in pancreatic cancer 
cells, suggesting a possible crosstalk between CAFs and 
tumor cells through Netrin G1/NGL1 signaling axis [64]. 
Further investigation revealed that a lack of Netrin G1 
in fibroblasts or lack of NGL1 in pancreatic cancer cells 
severely affected the ability of the latter to survive upon 
nutrient starvation. In addition, Netrin G1 expression 
in CAFs, through downstream p38MAPK activation, 
was found to be required to suppress NK cell-mediated 
cytotoxicity in the same model. Further, her team revealed 
that high expression levels of stromal Netrin G1 inversely 
correlate with PDAC patient overall survival. Taken 
together, the presented data indicate that Netrin G1+ CAFs 
provide better PDAC cell survival in nutrient-deprived 
environments, and means to escape from the immune 
system. Notably, it highlights the multiple roles CAFs play 
during tumor progression. As the field moves forward, 
TME researchers can build upon these studies that show 
stroma support tumor growth and resistance to treatment 
and/or stress in multiple environments.
Outstanding questions
This meeting fostered discussions of the needs 
and limitations of research currently focused on the 
components of the TME. Participating individuals are 
leading research programs to identify novel cell types, 
pathways of cellular interactions, model systems suitable 
for TME research questions, and to unravel heterogeneous 
cell populations. However, investigation of the TME 
components – and how they evolve throughout tumor 
progression, their role as drivers or suppressors of 
tumorigenesis, malignancy and/or partner with the tumor 
mass as co-organizers in tumor growth and respond to 
current therapeutics – remains limited. While progress has 
been made by several research programs in identifying 
novel CAF subpopulations, and initial traction is 
beginning to emerge with endothelial cells and adipocytes, 
standardized functional and molecular definitions for 
fibroblast subtypes (and other non-immune cells) do 
not yet exist. Tools to capture stromal heterogeneity 
are limited due to variable isolation techniques and the 
loss of cellular and microenvironmental context. Even 
with scRNA-seq data acquired to-date, lack of uniform 
analysis pipelines makes full utilization of the biological 
implications of this data difficult. 
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It would also be beneficial to create an accessible 
catalog of all cell types, spatial context, mechanical 
properties, and events that regulate them such that the field 
may begin to interpret what constitutes a supportive or 
resistant tumor stroma – or even sub-stromal compartments 
such as the perivascular niche that may uniquely protect 
tumor cells relative to other stromal regions. Similarly, it 
is not yet understood when a stroma becomes supportive 
of the tumorigenic process, when a suppressive stroma 
is lost or reprogrammed, and what determines this 
“stromagenic switch.” This includes the contribution of 
lifestyle factors, aging, and drug treatments that are likely 
to not only impact traditionally (and narrowly) defined 
tissue-specific microenvironments but also more broadly 
if the microenvironment is expanded to systemic effects as 
well. Another consideration is the changes in stroma from 
early (pre-neoplastic) disease through metastatic disease, 
which likely abide by stage-specific regulatory networks 
and yield unique changes for each cancer type. While many 
microfluidic or other engineered model systems are being 
developed to address the interactions of multiple cell types, 
development of new models may be necessary to address 
these fundamental questions.
Cells from multiple origins may perform similar 
functions. We have discussed CAF heterogeneity broadly 
in terms of function and marker expression, but these cells 
may be derived from a variety of sources, including bone 
marrow-derived mesenchymal stem cells, adipocytes, or 
even cancer cells which have undergone EMT [5]. Despite 
distinct origins, these precursors may converge into similar 
CAF functions, reinforcing the importance of key stromal 
cell functions in the TME. 
Finally, we need to determine what therapeutic 
opportunities exist within the TME that may improve the 
current standard-of-care for each cancer type and disease stage. 
Understanding some of the questions outlined above may 
unveil new therapeutic strategies, but widely useful platforms 
to test novel strategies both in primary and metastatic disease 
settings are also necessary, particularly because a response 
in the primary setting does not dictate a response in the 
metastatic setting. Likewise, established tumors are not one 
and the same as an early lesion, and are therefore unlikely to 
follow the same set of “biological rules.” Since the TME is 
complex and evolves with disease progression, there are many 
opportunities for discovery. Ultimately, a greater research 
effort in tumor stroma will lead to precision medicine with 
optimal therapeutic intervention and better patient outcomes.
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